Epidemiologic and laboratory classification systems for paralytic poliomyelitis cases

  • R. W. Sutter
  • S. L. Cochi
  • P. A. Patriarca


Classification systems for poliomyelitis cases were first developed in industrialized countries to provide a uniform and standardized method to assign epidemiological categories to individual cases, particularly for vaccine-associated paralytic poliomyelitis cases. The classification of paralytic poliomyelitis cases follows individual case investigations that attempt to collect all available clinical, epidemiologic and laboratory information on each suspected poliomyelitis case. Many countries have convened expert review committees to evaluate, confirm and classify suspected poliomyelitis cases. In the United States, classification systems for paralytic poliomyelitis cases have been in use since 1976. The goals of regional elimination of polio myelitis from the Americas by the year 1990, and of global eradication of poliomyelitis by the year 2000, provide an additional impetus to extend classification systems to poliomyelitisendemic areas and to standardize methods for monitoring progress towards these eradication objectives.


Case Definition Stool Specimen Acute Flaccid Paralysis Oral Poliovirus Vaccine Polio Eradication 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Strebel PM, Sutter RW, Cochi SL, Biellik RJ, Brink EW, Kew OM, Pallansch MA, Orenstein WA, Hinman AR (1992) Epidemiology of poliomyelitis in the United States one decade after the last reported case of indigenous wild virus-associated disease. Clin Infect Dis 14:568–579PubMedCrossRefGoogle Scholar
  2. 2.
    Kim-Farley RJ, Bart KJ, Schonberger LB, Orenstein WA, Nkowane BM, Hinman AR, Kew OM, Hatch MH, Kaplan JE (1984) Poliomyelitis in the U.S.A.: Virtual elimination of disease caused by wild virus. Lancet ii: 1315–1317CrossRefGoogle Scholar
  3. 3.
    Expanded Programme on Immunization (1992) Global overview of poliomyelitis. Geneva, Switzerland: World Health Organization, 1992 (Technical Commission Document 56.1)Google Scholar
  4. 4.
    Robertson SE, Chan C, Kim-Farley R, Ward N (1990) Worldwide status of poliomyelitis in 1986, 1987 and 1988, and plans for its global eradication by the year 2000. World Health Stat Q 43: 81–90Google Scholar
  5. 5.
    Horstmann DM, Quinn TC, Robbins FC (eds) (1984) International Symposium on Poliomyelitis Control. Rev Inf Dis 6 [Suppl]: 301–601Google Scholar
  6. 6.
    Nathanson N (1982) Eradication of poliomyelitis in the United States. Rev Inf Dis 4: 940–945CrossRefGoogle Scholar
  7. 7.
    Resolution of the 41st World Health Assembly (1988) Global Eradication of Poliomyelitis by the Year 2000. Geneva, Switzerland: World Health Organization (WHA 41.28)Google Scholar
  8. 8.
    Expanded Programme on Immunization (1991) EPI global overview. Geneva, Switzerland: World Health Organization (EPI/GAG/WP.l)Google Scholar
  9. 9.
    Hinman AR, Foege WH, de Quadros CA, Patriarca PA, Orenstein WA, Brink EW (1987) The case for global eradication of poliomyelitis. Bull WHO 65:835–840PubMedGoogle Scholar
  10. 10.
    Sutter RW, Brink EW, Cochi SL, Kew OM, Orenstein WA, Biellik RJ, Hinman AR (1989) A new epidemiologic and laboratory classification system for paralytic poliomyelitis cases. AmJ Public Health 79:495–498CrossRefGoogle Scholar
  11. 11.
    Expanded Programme on Immunization (1989) Global poliomyelitis eradication by the year 2000. Manual for managers of immunization programmes. Geneva, Switzerland: World Health Organization (WHO/EPI/POLIO/89.1)Google Scholar
  12. 12.
    Centers for Disease Control (1990) Case definitions for public health surveillance. MMWR 39 (RR-13): 1–43Google Scholar
  13. 13.
    Biellik RJ, Bueno H, Olive JM, de Quadros C (1992) Poliomyelitis case confirmation: characteristics for use by national eradication programmes. Bull WHO 70: 79–84PubMedGoogle Scholar
  14. 14.
    Andrus JK, de Quadros C, Olivé JM, Hull HF (1992) Screening for acute flaccid paralysis for polio eradication: Ways to improve specificity. Bull WHO 70: 591–596PubMedGoogle Scholar
  15. 15.
    Dietz V, Lezana M, Sancho CG, Montesano R (1992) Predictors of poliomyelitis case confirmation at initial clinical evaluation: Implications for poliomyelitis eradication in the Americas. Int J Epidemiol 21: 800–806PubMedCrossRefGoogle Scholar
  16. 16.
    Andrus JK, de Quadros CA, Olivé JM (1992) The surveillance challenge: Final stages of eradication of poliomyelitis in the Americas. MMWR 41: 21–26PubMedGoogle Scholar
  17. 17.
    de Quadros CA, Andrus JK, Olivé JM, de Macedo CG (1992) Polio eradication from the Western hemisphere. Ann Rev Publ Health 13: 239–252CrossRefGoogle Scholar
  18. 18.
    Centers for Disease Control (1988) Guidelines for evaluating surveillance systems. MMWR 37: 1–18Google Scholar
  19. 19.
    Expanded Program on Immunization (1988) Polio eradication field guide. 2nd edition, Washington, DC: Pan American Health Organization (ISBN 92 75 13006X)Google Scholar
  20. 20.
    Wharton M (1992) Evaluation of weekly negative reporting of acute flaccid paralysis, Venezuela, 1991. PAHO Bull 14:4–5Google Scholar
  21. 21.
    Wright PF, Kim-Farley RJ, Robertson SE, Scott RM, Ward NA, Henderson RH (1991) Strategies for the global eradication of poliomyelitis by the year 2000. N Engl J Med 325:1174–1179CrossRefGoogle Scholar
  22. 22.
    World Health Organization (1989) Laboratory support for poliomyelitis eradication: Memorandum from a WHO meeting. Bull WHO 67: 365–367Google Scholar
  23. 23.
    Expanded Programme on Immunization (1990) Global poliomyelitis eradication by the year 2000. Manual for the virological investigation of poliomyelitis. Geneva, Switzerland: World Health Organization (WHO/EPI/CDS/POLIO/90.1.)Google Scholar
  24. 24.
    Centers for Disease Control (1990) Update: Progress toward eradicating poliomyelitis from the Americas. MMWR 39: 557–561Google Scholar
  25. 25.
    de Quadros CA, Andrus JK, Olivé JM, da Silveira C, Eikhof RM, Carrasco P, Fitzsimmons JW, Pinheiro FP (1991) Eradication of poliomyelitis: progress in the Americas. Pediatr Infect Dis J 10: 222–229PubMedCrossRefGoogle Scholar
  26. 26.
    Gear JHS (1984) Nonpolio causes of polio-like paralytic syndromes. Rev Infect Dis 6 [Suppl]: 379–384CrossRefGoogle Scholar
  27. 27.
    Melnick JL (1984) Enterovirus type 71 infections: A varied clinical pattern sometimes mimicking paralytic poliomyelitis. Rev Infect Dis 6 [Suppl]: 387–390CrossRefGoogle Scholar
  28. 28.
    Nkowane BM, Wassilak SG, Orenstein WA, Bart KJ, Schonberger LB, Hinman AR, KewOM (1987) Vaccine-associated paralytic poliomyelitis. United States: 1973 through 1984. JAMA 257: 1335–1340PubMedCrossRefGoogle Scholar
  29. 29.
    Poliomyelitis Surveillance Summary: 1979. Atlanta, Centers for Disease Control, April 1981.Google Scholar
  30. 30.
    Schonberger LB, McGowan JE, Gregg MB (1976) Vaccine-associated poliomyelitis in the United States: 1961-1972. Am J Epidemiol 104: 202–211PubMedGoogle Scholar
  31. 31.
    Nakano JH, Hatch MH, Thieme ML, Nottay B (1978) Parameters for differentiating vaccine-derived and wild poliovirus strains. Prog Med Virol 24: 178–206PubMedGoogle Scholar
  32. 32.
    van Wezel AL, Hazendonk AG (1979) Intratypic serodifferentiation of poliomyelitis virus by strain-specific antisera. Intervirology 11: 2–8PubMedCrossRefGoogle Scholar
  33. 33.
    Humphrey DD, Kew OM, Feorino PM (1982) Monoclonal antibodies of four different specificities for neutralization of type 1 polioviruses. Infect Immun 36: 841–843PubMedGoogle Scholar
  34. 34.
    Minor PD, Schild GC, Ferguson M, Mackay A, Magrath DI, John A, Yates PJ, Spitz M (1982) Genetic and antigenic variation in type 3 polioviruses: Characterization of strains by monoclonal antibodies and Tl oligonucleotide mapping. J Gen Virol 61: 167–176PubMedCrossRefGoogle Scholar
  35. 35.
    Crainic R, Couillin P, Blondel B, Cabau N, Boue A, Horodniceanu F (1983) Natural variation of poliovirus neutralization epitopes. Infect Immun 41: 1217–1225PubMedGoogle Scholar
  36. 36.
    Osterhaus ADME, van Wezel AL, Hazendonk TG, Uytdehaag FGCM, van Asten 4JAAM, van Steenis B (1983) Monoclonal antibodies to polioviruses. Comparison of intratypic strain differentiation of poliovirus type 1 using monoclonal antibodies versus crossadsorbed antisera. Intervirology 20: 129–136PubMedCrossRefGoogle Scholar
  37. 37.
    Kew OM, Nottay BK, Obijeski JF (1984) Applications of oligonucleotide fingerprinting to the identification of viruses. In: K. Maramorosch and K. Koprowski (eds). Methods in Virology. Academic Press, New York, 8:41–84Google Scholar
  38. 38.
    Rico-Hesse R, Pallansch MA, Nottay BK, Kew OM (1987) Geographic distribution of wild poliovirus type 1 genotypes. Virology 160: 311–322PubMedCrossRefGoogle Scholar
  39. 39.
    da Silva EE, Pallansch MA, Holloway BP, Cuoto Oliveira MJ, Schatzmayr HG, Kew OM (1991) Oligonucleotide probes for the detection of the wild poliovirus types 1 and 3 endemic to Brazil. Intervirology 32: 149–159PubMedGoogle Scholar
  40. 40.
    Yang Chen-Fu, De L, Holloway BP, Pallansch MA, Kew OM (1991) Detection and identification of vaccine-related polioviruses by the polymerase chain reaction. Virus Res 20:159–179CrossRefGoogle Scholar
  41. 41.
    Hayward JC, Gillespie SM, Kaplan KM, Packer R, Pallansch M, Plotkin S, Schonberger LB (1989) Outbreak of poliomyelitis-like paralysis associated with enterovirus 71. Pediatr Infect Dis J 8:611–616PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag/Wien 1993

Authors and Affiliations

  • R. W. Sutter
    • 1
  • S. L. Cochi
    • 1
  • P. A. Patriarca
    • 1
  1. 1.Division of ImmunizationCenters for Disease Control and PreventionAtlantaUSA

Personalised recommendations